Neuro Therapia
Ohio
About Neuro Therapia
NeuroTherpia develop new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $23.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2024)
- Website: neurotherapia.com
- Phone: (216)870-7969
Industries & Categories
Health Care, Neuroscience, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neuro-therapia-91229 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.